Furthermore, the incomplete eradication of the tumor in mice receiving the NIS+ Antares+ CAR NK cell therapy could indicate insufficient numbers of therapeutic cells (either at time of administration or their in vivo persistence). This evidence concerns the gene SLC5A5 and neoplasm.